Pdt Partners, LLC Prelude Therapeutics Inc Transaction History

Pdt Partners, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$5.0 - $8.82 $155,450 - $274,213	-31,090 Reduced 71.09%	12,641 $84,000
Q2 2022 Aug 15, 2022	SELL	$4.0 - $7.55 $112,364 - $212,087	-28,091 Reduced 39.11%	43,731 $228,000
Q1 2022 May 16, 2022	BUY	$6.9 - $13.22 $247,813 - $474,796	35,915 Added 100.02%	71,822 $496,000
Q4 2021 Feb 14, 2022	BUY	$11.89 - $31.74 $426,934 - $1.14 Million	35,907 New	35,907 $447,000

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $47.3M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.